GlassScriptPhysician profile
Martha A Phillips
NPI 1730578303
$2,459.77
in general payments reported to CMS, 2019-2025
11 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $437 · 2023: $395 · 2024: $847 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904 · Education: $18.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.59 |
| Education | $18.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.94 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $361.29 | 2021-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $285.71 | 2023-2024 | Auvelity |
| Neurocrine Biosciences, INC. | $279.83 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $249.77 | 2022-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $228.65 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $219.03 | 2021-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $177.05 | 2022-2025 | Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.99 | 2025 | Jardiance |
| Lundbeck LLC | $66.11 | 2021-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.